FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1633-1637 June 1, 2000 Number 22 Next

	Full Text PDF Editorial by Sartor, R. B. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Crohn's disease is a chronic inflammatory disorder of the bowel. In a preliminary study, we evaluated whether the administration of growth hormone (somatropin) as well as a high-protein diet would ameliorate the symptoms of the disease.

Methods We randomly assigned 37 adults with moderate-to-severe active Crohn's disease to four months of self-administered injections of growth hormone (loading dose, 5 mg per day subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day) or placebo. We instructed all patients to increase their protein intake to at least 2 g per kilogram of body weight per day. Patients continued to be treated by their usual physicians and to receive other medications for Crohn's disease. The primary end point was the change in scores on the Crohn's Disease Activity Index from base line to month 4. Scores can range from 0 to 600, with higher scores indicating more disease activity.

Results At base line, the mean (±SD) score on the Crohn's Disease Activity Index was somewhat higher among the 19 patients in the growth hormone group than among the 18 patients in the placebo group (287±134 vs. 213±120, P=0.09). Three patients in the placebo group withdrew before their first follow-up visit and were not included in the data analysis. At four months, the Crohn's Disease Activity Index score had decreased by a mean of 143±144 points in the growth hormone group, as compared with a decrease of 19±63 points in the placebo group (P=0.004). Side effects in the growth hormone group included edema (in 10 patients) and headache (in 5) and usually resolved within the first month of treatment.

Conclusions Our preliminary study suggests that growth hormone may be a beneficial treatment for patients with Crohn's disease.

Source Information

From the Departments of Pediatrics (A.E.S., L.B., M.B.D., T.G., M.A.W.) and Medicine (M.J.M.), North Shore University Hospital and New York University School of Medicine, Manhasset. Presented at the 81st annual meeting of the Endocrine Society, San Diego, Calif., June 12–15, 1999.

Address reprint requests to Dr. Slonim at the Department of Pediatrics, North Shore University Hospital, 300 Community Dr., Manhasset, NY 11030, or at slonim{at}nshs.edu.

Full Text of this Article

This article has been cited by other articles:

• Schnabel, D., Grasemann, C., Staab, D., Wollmann, H., Ratjen, F., for the German Cystic Fibrosis Growth Hormone Stud, (2007). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Metabolic and Respiratory Effects of Growth Hormone in Children With Cystic Fibrosis. Pediatrics 119: e1230-e1238 [Abstract] [Full Text]  
• Peyrin-Biroulet, L., Chamaillard, M., Gonzalez, F., Beclin, E., Decourcelle, C., Antunes, L., Gay, J., Neut, C., Colombel, J.-F., Desreumaux, P. (2007). Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. Gut 56: 577-583 [Full Text]  
• Han, X, Benight, N, Osuntokun, B, Loesch, K, Frank, S J, Denson, L A (2007). Tumour necrosis factor {alpha} blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis. Gut 56: 73-81 [Abstract] [Full Text]  
• Han, X., Osuntokun, B., Benight, N., Loesch, K., Frank, S. J., Denson, L. A. (2006). Signal Transducer and Activator of Transcription 5b Promotes Mucosal Tolerance in Pediatric Crohn's Disease and Murine Colitis. Am. J. Pathol. 169: 1999-2013 [Abstract] [Full Text]  
• Fruchtman, S., Simmons, J. G., Michaylira, C. Z., Miller, M. E., Greenhalgh, C. J., Ney, D. M., Lund, P. K. (2005). Suppressor of cytokine signaling-2 modulates the fibrogenic actions of GH and IGF-I in intestinal mesenchymal cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G342-G350 [Abstract] [Full Text]  
• Sandborn, W J, Faubion, W A (2004). Biologics in inflammatory bowel disease: how much progress have we made?. Gut 53: 1366-1373 [Full Text]  
• Nayar, M, Rhodes, J M (2004). Management of inflammatory bowel disease. Postgrad. Med. J. 80: 206-213 [Abstract] [Full Text]  
• Dahly, E. M., Miller, M. E., Lund, P. K., Ney, D. M. (2004). Postreceptor Resistance to Exogenous Growth Hormone Exists in the Jejunal Mucosa of Parenterally Fed Rats. J. Nutr. 134: 530-537 [Abstract] [Full Text]  
• Podolsky, D. K. (2002). Inflammatory Bowel Disease. NEJM 347: 417-429 [Full Text]  
• Abreu, M. T., Arnold, E. T., Chow, J. Y. C., Barrett, K. E. (2001). Phosphatidylinositol 3-Kinase-dependent Pathways Oppose Fas-induced Apoptosis and Limit Chloride Secretion in Human Intestinal Epithelial Cells. IMPLICATIONS FOR INFLAMMATORY DIARRHEAL STATES. J. Biol. Chem. 276: 47563-47574 [Abstract] [Full Text]  
• (2000). New Approaches to Crohn's Disease. Journal Watch Dermatology 2000: 16-16 [Full Text]  
• (2000). Growth Hormone for Crohn's Disease. JWatch Gastroenterology 2000: 11-11 [Full Text]  
• (2000). New Approaches to Crohn's Disease. JWatch General 2000: 4-4 [Full Text]  
• Sartor, R. B. (2000). New Therapeutic Approaches to Crohn's Disease. NEJM 342: 1664-1666 [Full Text]